112 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Completed A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
Conditions: Non-Small-Cell Lung Carcinoma;   Neoplasm Recurrence, Local
Interventions: Drug: Avastin  (bevacizumab);   Drug: Tarceva (erlotinib HCl)
3 Active, not recruiting Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: paclitaxel;   Drug: sorafenib tosylate;   Other: placebo
4 Active, not recruiting GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Lung Cancer, Non-Small Cell
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
5 Recruiting STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: 5-fluorouracil;   Drug: bevacizumab [Avastin];   Drug: capecitabine [Xeloda];   Drug: fluoropyrimidine-based chemotherapy;   Drug: irinotecan;   Drug: leucovorin;   Drug: oxaliplatin
6 Completed Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Condition: Kidney Cancer
Intervention: Drug: atrasentan hydrochloride
7 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
8 Completed Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Drug: temozolomide
9 Recruiting A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: LY2875358;   Drug: Erlotinib
10 Active, not recruiting Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Other: Placebo
11 Active, not recruiting Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Anastrozole
12 Active, not recruiting Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation
Interventions: Drug: tipifarnib;   Procedure: clinical observation
13 Terminated Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
Condition: Prostate Cancer
Intervention: Drug: Oral Satraplatin
14 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
15 Active, not recruiting A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo
16 Active, not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
17 Active, not recruiting Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
18 Active, not recruiting Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: selumetinib;   Drug: oxaliplatin;   Drug: fluorouracil
19 Recruiting Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
20 Active, not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years